MYC and medulloblastoma: Additionally, their medulloblastoma model showed sensitivity towards tazemetostat, an EZH2 inhibitor, suggesting it may be a potential drug for Group 3 medulloblastoma patients overexpressing OTX2 and c-MYC [129].